RxDoctor Payments Data

Sindhu Avula, MD

Interventional Cardiology · Topeka, KSNPI 1811371974

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $11,097 of the $17,858 with a category attached, or 62.1%. 23 manufacturers reported payments, led by Boston Scientific at 27.9% of the total. Reporting peaked in 2022 at $7,013 and has fallen 79.0% since, to $1,470 in 2025.

$17,858in general payments, 2019–2025

Across 199 payments — averaging $89.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Medtronic$3K
  • Abbott$3K
  • Bard Peripheral Vascular, Inc.$1K
  • BD$1K
  • Biotronik Inc.$1K
  • plus $2K from 17 others

What the payments were for

  • Grants$1,1056%
  • Travel & lodging$11,09762%
  • Food & beverage$5,45831%
  • Education$1981%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,858 in reported general payments places this provider in the 70th percentile of 55 interventional cardiology providers in Kansas.

See all interventional cardiology providers in Kansas

Medicare billing

Part B allowed, 2024
$80,963
Medicare patients
409
Services billed
947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$58,543
Rosuvastatin Calcium149$1,437
Metoprolol Succinate155$1,241
Ezetimibe61$1,054
Atorvastatin Calcium124$985
Potassium Chloride15$537
ClopidogrelClopidogrel Bisulfate70$517
Amlodipine Besylate64$485
Carvedilol52$437
Losartan Potassium49$306
Furosemide67$234
Lisinopril43$233
Nitroglycerin12$219
Isosorbide Mononitrate ErIsosorbide Mononitrate27$215
Hydrochlorothiazide42$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$58,54372 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 55 interventional cardiology providers in Kansas.

Other interventional cardiology in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →